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A B S T R A C T
Background: The holistic management of tuberculosis (TB) patients can improve life expectancy and lost
organ function.
Rehabilitation: Chronic sequelae are very common among patients who survive TB, which can lead to a
further decline in lung function. There is still no guidance for ‘cured’ patients with impaired lung function
who need pulmonary rehabilitation. Additional tests for evaluation should be given after the end of
treatment, as recent studies have shown the good effect of pulmonary rehabilitation for TB patients.
Optimized nutritional care: Malnutrition is very common among TB patients and is related to
malabsorption. The latter can cause lower drug exposure, which may result in treatment failure,
increasing the risk of death, and can lead to acquired drug resistance. Malnutrition should be assessed
according to the Global Leadership Initiative on Malnutrition (GLIM) criteria and the diagnosis should
lead to an individualized treatment plan, including sufficient proteins and preferably in combination with
adequate training.
Protective immune responses: Under normal circumstances, most immune cells use a glucose-based
mechanism to generate energy. Therefore the patient’s nutritional status is a key factor in shaping immune
responses. Disease-related malnutrition leads to proteolysis and lipolysis. In the end, the identification of
individuals who will benefit from immune-modulatory strategies may lead to clinically relevant markers.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Tuberculosis (TB) remains an important cause of mortality
globally; however, very little is said of the hundreds of millions of
patients who survive the disease. Chronic sequelae are very
common, which can range from reduced lung function and post-TB
bronchiectasis to aspergilloma and non-tuberculous infections, all
of which can further impact lung function. We are only now
gaining a better insight into TB as a systemic inflammatory process
and understanding that patients are more likely to suffer from
vascular events after TB cure. Our ex-TB patients can be expected to
be more fragile (Choi et al., 2017a) and are still likely to die 4 yearsciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
ningen from ClinicalKey.com by Elsevier on March 30, 2020.
ion. Copyright ©2020. Elsevier Inc. All rights reserved.
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question is, why is this the case and what can be done about it?
The following article discusses the state of the art on the holistic
management of TB patients aimed at recuperating lost organ
function and raising post-TB life-expectancy, as well as topics for
future research in the field. In particular the review is focused on
(1) the functional evaluation of TB patients at the end of treatment
and rehabilitation of sequelae; (2) optimization of nutritional care,
and (3) new insights into the protective immune response.
Methods
A non-systematic review of the literature was conducted by the
members of the writing committee, so as to include useful core
references that may help the reader better understand the topics
covered. The following keywords were used, without any time
limitation: ‘tuberculosis’, ‘functional evaluation’, ‘pulmonary
rehabilitation’, ‘nutrition’, ‘protective immune response’. MEDLINE
was used as the search engine, focusing on the English-language
literature only.
Rehabilitation for TB patients
Functional evaluation of patients and pulmonary rehabilitation
TB control programmes have prioritized early diagnosis and
effective treatment of infectious cases to ensure rapid cure of
individual patients and interruption of the transmission chain.
Given most of the global TB burden is localized in countries with
limited economic resources, the importance of investigating the
functional status of the patients declared ‘cured’ to assess potential
abnormalities and candidates for pulmonary rehabilitation has not
gained much attention (Amaral et al., 2015; Muñoz-Torrico et al.,
2016; Spruit et al., 2013).
With a main focus on chronic obstructive pulmonary disease
(COPD), the American Thoracic Society/European Respiratory
Society (ATS/ERS) rehabilitation guidelines indicate that rehabili-
tation is an effective intervention in chronic respiratory diseases,
although TB is not individually mentioned. Recent evidence has
shown that obstructive and/or restrictive functional sequelae may
occur, potentially affecting quality of life (QoL) (Amaral et al., 2015;
Muñoz-Torrico et al., 2016). Currently, no guidance on specific
indications and procedures regarding the study and rehabilitation
of TB sequelae is available (Amaral et al., 2015; Muñoz-Torrico
et al., 2016), although TB rehabilitation was recently recommended
in the ATS/ERS/Infectious Disease Society of America (IDSA)/
Centers for Disease Control and Prevention (CDC) multidrug-
resistant (MDR)-TB guidelines (Nahid et al., 2019).
The preliminary data available suggest that pulmonary rehabili-
tation is effective in patients with a previous history of TB and with
impaired lung function. As more and more countries are potentially
able to financially support rehabilitation for patients with post-TB
sequelae, well-designed prospective studies are necessary to
identify the individuals needing further assessment and to clarify
which rehabilitation models can be implemented to ensure a
functional recovery (Visca et al., 2019).
The evidence available on lung function impairment
A few studies have investigated mechanical lung function in TB
patients. Already in 1961, Hallet and Martin described a ‘diffuse
obstructive pulmonary syndrome’ among TB patients admitted to
sanatoria (Hallett and Martin, 1961). Willcox and Ferguson (1989)
identified airway obstruction in 68% of patients completing anti-TB
treatment, with an inverse relationship between the extent of
chest radiography lesions and forced expiratory volume in the firstDownloaded for Anonymous User (n/a) at University of Groninge
For personal use only. No other uses without permission. Csecond (FEV1). Similarly, in South Africa, TB was found to be
responsible for lung function impairment (Hnizdo et al., 2000). In a
large population-based study involving 14 050 participants from
18 countries, a history of previous anti-TB treatment was
associated with both airflow obstruction and spirometry restric-
tion, and it was concluded that TB is a major cause of COPD in
countries with a high TB prevalence (Amaral et al., 2015).
Worldwide, several studies have identified TB (treatment) as
a positive predictor for loss of lung function. The conclusions of a
South Korean study conducted between 2008 and 2012
recommended coupling regular lung function testing and
smoking cessation as preventive measures for chronic airway
obstruction (Jung et al., 2015). A study conducted in India in
2015 identified obstructive, restrictive, and mixed lung
impairment disorders in TB patients after completing their
treatment (Sailaja and Nagasreedhar, 2015). In China, treated TB
was identified as an independent risk factor for airflow
obstruction (Lam et al., 2010). In Papua New Guinea, effective
management (early diagnosis and adequate treatment) of MDR-
TB patients was considered essential to prevent post-treatment
sequelae (Ralph et al., 2013).
Furthermore, a multicentre population-based study in Latin
America involving over 5500 patients in five cities revealed that
(self-reported) history of previous anti-TB treatment was signifi-
cantly associated with airflow obstruction (Menezes et al., 2007).
In Mexico, 70 patients cured of pulmonary TB were investigated,
and frequent obstructive abnormalities were found, with impaired
QoL (de la Mora et al., 2015). Last, in Texas, United States,
pulmonary function was evaluated twice, after 20 weeks and at
the end of anti-TB treatment, and TB treatment was identified
as an independent risk factor for COPD, both in smokers and
non-smokers (Vecino et al., 2011).
Therefore, it was recently suggested that lung function be
assessed by performing spirometry, plethysmography, DLCO
(diffusion for carbon oxide), arterial blood gas analyses, and
evaluating the capacity to perform exercise via the 6-min walk
test (6MWT). It is possible to describe the lesions with chest
radiography and computed tomography before and after
treatment. Clearly, the clinical assessment of infectious cases
implies adequate infection control measures are in place
(Migliori et al., 2019).
The evidence available on pulmonary rehabilitation
TB is clearly mentioned among the conditions for which
pulmonary rehabilitation is useful according to the ATS/ERS
guidelines and the South African COPD management guidelines
(Spruit et al., 2013). In a recent study (Visca et al., 2019), pulmonary
rehabilitation was effective in patients with a previous history of
anti-TB treatment. Patients with impaired lung function reported a
significant improvement in 6MWT, Borg dyspnoea and fatigue
scores, FEV1, forced vital capacity (FVC), mean arterial oxygen
partial pressure (PaO2), and median arterial blood oxygen
saturation (SaO2) (Visca et al., 2019).
In a recent editorial and in studies conducted in Benin,
Zimbabwe, and Uganda (Chin et al., 2019; Fiogbe et al., 2019;
Harries and Chakaya, 2019; Jones et al., 2017), the issue of the
feasibility of post-treatment functional assessment of TB patients
and subsequent pulmonary rehabilitation was discussed, with a
focus on the perspective of low-income countries. In Uganda, a
pulmonary rehabilitation package supervised by physiotherapists
and requiring minimum equipment initiated at the health facility
level, with aerobic and resistance exercises later managed at home,
was demonstrated to be feasible and associated with clinically
important improvements in QoL, exercise capacity, and respiratory
outcomes (Jones et al., 2017).n from ClinicalKey.com by Elsevier on March 30, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
S12 O.W. Akkerman et al. / International Journal of Infectious Diseases 92S (2020) S10–S14A recent review (Hoger et al., 2014) recommended that future
evaluation of post-treatment sequelae include the following
(Figure 1): detailed information on patient characteristics (age,
sex, ethnicity, etc.), TB disease (history of previous treatment,
bacteriological status and pattern of drug resistance, previous
drugs and regimens with adverse events), and pathophysiological
status (spirometry with bronchodilator response), assessment of
lung volumes (plethysmography), DLCO, arterial blood gases
analysis, 6MWT, radiological evaluation, QoL evaluation, rationale
and the features of the rehabilitation plan (with clear pre-/post-
test comparisons), and a cost evaluation. Furthermore, studies
should quantify the proportion of patients needing rehabilitation
among those completing treatment. This will allow the need for
pulmonary rehabilitation to be estimated and adequately planned
at the programmatic level.
Optimized nutritional care for TB patients
The history of nutritional care
Nutritional care has been an important component of TB
treatment throughout the history of European civilization.
Lacking adequate drugs, Hippocrates’ TB treatment consisted of
resting, praying, drinking milk, exercise, and avoiding extreme
weather conditions (Madkour et al., 2004). At the end of the
nineteenth century, in the first sanatorium for TB patients, a more
specific nutritional regimen was implemented in TB treatment.
This diet was “a mix of meat with plenty of vegetables” (Kinghorn,
1921). Furthermore, to treat symptoms like night sweats, cognac
was used (Kinghorn, 1921). In the first randomized trial testing
the potential of streptomycin injections, the control standard of
care consisted of nutrition and bed rest (Streptomycin in
Tuberculosis Trials Committee, 1948). In 2013, the World Health
Organization (WHO) published the first guidelines on nutritional
care and support specifically for patients with TB. In these
guidelines, the WHO stressed that all patients with active TB
are entitled to individualized nutritional assessment and
management, including counselling and therapy (World Health
Organization, 2013).Figure 1. Summary of the core interventions at the end of anti-tuberculosis treatment
DLCO: diffusing capacity of the lung for carbon monoxide; Sat HB%: haemoglobin saturati
6MWT: 6-min walking test; CT: computed tomography; QoL: quality of life; PR: pulmo
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Malnutrition is defined by the European Society for Clinical
Nutrition and Metabolism (ESPEN) as “a state resulting from lack of
intake or uptake of nutrition that leads to altered body composi-
tion (decreased fat-free mass) and body cell mass leading to
diminished physical and mental function and impaired clinical
outcome from disease” (Cederholm et al., 2017). In general,
malnutrition is reported to have a huge impact on patient
outcomes and healthcare costs (Muscaritoli et al., 2017).
Disease-related malnutrition is characterized by a loss of fat-free
mass; therefore, normal weight, overweight, and obese patients
with TB can be malnourished (Paton et al., 2004). This implies a
decline in muscle function, which leads to dependency and less
participation in society for the patient. Regaining physical function
shortens the time needed for recovery and enables patients with
TB to resume work (Cederholm et al., 2017; Paton et al., 2004). The
prevalence of malnutrition in patients with TB is calculated to be
70%, and in this population, malnutrition is associated with a two-
fold higher risk of dying from TB (Bhargava et al., 2013).
Malnutrition is considered an important potentially reversible
risk factor for TB treatment failure (Choi et al., 2017b). It is
hypothesized that pharmacokinetic variability, resulting from
changes in malabsorption (Montalto et al., 2008), can influence
efficacy. Patients with TB may suffer from malabsorption because of
malnutrition, which can be increased by possible comorbidities such
as diabetes and HIV/AIDS. Subsequently, decreased absorption of
anti-TB drugs is likely to result in low drug exposure. This may lead to
unfavourable outcomes by treatment failure and the development of
drug resistance (Ter Beek et al., 2019).
Nutritional assessment, therapy, and monitoring
Malnutrition is not disease-specific but is a ‘nutrition disorder’
(Cederholm et al., 2017). As low body mass index (BMI) is a
hallmark of chronic malnutrition that involves the loss of both fat
and muscle tissue, a BMI < 18.5 kg/m2may be used as a measure for
general public health purposes (Cederholm et al., 2015). However,
in clinical practice, using BMI exclusively is of less relevance for
nutritional assessment, since in disease-related malnutrition, and during pulmonary rehabilitation.
on as a percentage; PaO2/PaCO2: arterial blood tension of oxygen and carbon dioxide;
nary rehabilitation.
ngen from ClinicalKey.com by Elsevier on March 30, 2020.
. Copyright ©2020. Elsevier Inc. All rights reserved.
Figure 2. Immune responses in Mycobacterium tuberculosis infection. Tissue resident T-cells (Trm) and tumour infiltrating T-cells (TIL) exhibit increased Bhlhle40 expression;
however, this is not the case for peripheral (CD8+) T-cells. GAL (granuloma-associated lymphocytes; Tully et al; 2005) correspond to TIL. Increased Bhlhle40 is associated with
increased immune effector functions, increased ‘mitochondrial fitness’, and increased competence to contain pathogens or transformed cells (light green arrow). In contrast,
decreased Bhlhe40 expression is linked with loss of immune competence (dark green arrow). Immune cells may be recruited into the granuloma via Trm resources, from the
peripheral circulation, or from lymph nodes. TCF1+ PD1+ T-cells have stem-like properties and are crucial in long-term immune memory. Antigen-specific CD8+ T-cells are
vital for immune surveillance, but may also be responsible for mediating cachexia.
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standard for malnutrition is not available, which complicates
consensus on how nutritional assessment and its validation should
be conducted. However, in 2018, consensus diagnostic criteria for
malnutrition were published by ESPEN and the American Society
for Parenteral and Enteral Nutrition (ASPEN) to accommodate
uniformity in nutritional assessment, i.e. the ‘GLIM criteria’ (Global
Leadership Initiative on Malnutrition) (Cederholm et al., 2019).
These criteria are both phenotypic (weight loss, low BMI, reduced
muscle mass) and aetiological (reduced food intake or assimila-
tion, disease burden/inflammatory condition), and are preceded by
validated screening for malnutrition risk (Cederholm et al., 2019).
After diagnosing malnutrition, an individualized treatment
plan needs to be developed. This tailored treatment plan needs to
be based on sufficient proteins (and distribution) and energy from
either regular foods or medical nutritional supplements if
necessary, and preferably in combination with training (Ockenga
et al., 2006). The nutritional counselling and measurements that
are performed to assess malnutrition should be repeated regularly
during the treatment and (pulmonary) rehabilitation period, to
allow adjustment of the nutritional treatment plan if necessary.
New insights from protective immune responses—cross-
fertilizing concepts for anti-MTB immune surveillance
New insights from cancer research and biological therapy are
guiding innovative immunological therapies targeted against
defined molecular targets. A novel pathway has been suggested
on how disease-related malnutrition is mediated, and is a common
finding in TB patients. Nutritional status is a key factor in shaping
immune responses. Under normal circumstances, most immune
cells use a glucose-based mechanism to generate energy. In
nutrient-deficient states, alternative sources are used to generate
energy, such as proteins and fatty acids. Baazim et al. showed that
infection-induced cachexia is not only mediated by tumour
necrosis factor alpha (TNF-α), interleukin (IL)-1β, and IL-6 leading
to proteolysis and lipolysis, but also by antigen-specific CD8+
T-cells that mediate cachexia by adipose tissue remodelling
(Baazim et al., 2019) (Figure 2). Furthermore, the containment
of tissue infections requires the involvement of tissue resident
immune cells (Trm cells). These cells are enriched in the lung and
are thought to mediate an important line of defence against
invading pathogens (Behr et al., 2018). Bhlh40 is a key factor
mediating containment of infectious pathogens (or transformed
cells) (Li et al., 2019). Mice with reduced Bhlhle40 cells exhibit
reduced survival in influenza-positive animals; increased Bhlhle40Downloaded for Anonymous User (n/a) at University of Groninge
For personal use only. No other uses without permission. Cexpression results in increased interferon-gamma production in
the Th1 compartment. These may be promising clinically relevant
markers to identify individuals who may benefit from immune-
modulatory strategies targeting the biological pathways associated
with long-term protective immune responses.
Conclusions
In this review on the holistic approach to TB patients, we have
discussed the recent evidence on the importance of evaluating
functional status at the completion of treatment in order to
identify candidates for pulmonary rehabilitation. We have shown
that pulmonary rehabilitation is effective in improving functional
parameters, the capacity to perform exercise (walking test), and
quality of life. We have described the recent evidence and
implications at the immunological level, identifying priorities for
future research. We have also discussed the damage produced by
malnutrition and the importance of assessing the nutritional
status. The importance of addressing malnutrition correctly and
in a timely fashion is essential in reducing morbidity and
mortality.
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